A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?

Basit Öğe Kaydı
dc.authorid0000-0002-4607-5724
dc.authorid0000-0001-9975-5507
dc.contributor.authorGüler, Ekrem
dc.contributor.authorGüler, Gamze Babür
dc.contributor.authorDemir, Gültekin Günhan
dc.contributor.authorHatipo?lu, Suzan
dc.date.accessioned08.07.201910:49:13
dc.date.accessioned2019-07-08T20:18:51Z
dc.date.available08.07.201910:49:13
dc.date.available2019-07-08T20:18:51Z
dc.date.issued2015
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractObesity is a significant cause of morbidity and mortality, and it is becoming increasingly prevalent worldwide. Altered pharmacodynamics and pharmacokinetics of drugs in obese patients require dose adjustment according to body weight. New oral anticoagulants (NOACs), which are more frequently used for anticoagulation, are recommended to be used at a fixed dose based on data derived from phase 2 and 3 studies. However, the representation of obese patients [>100 kg or a body mass index (BMI) of >30 kg/m] in subgroups with a small sample size and reports of various emboli cases under drug treatment have raised suspicions about the adequacy of fixed dose use. To address this issue, we analyzed several patients with a body weight of >100 kg or BMI of >30 kg/m participating in NOAC studies and evaluated whether these numbers were sufficient to enable an accurate recommendation of fixed dose use in obese patients.
dc.identifier.citationGüler, E., Güler, G. B., Demir, G. G. ve Hatipo?lu, S. (2015). A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? The Anatolian Journal of Cardiology, (15)2, 1020-1029. https://doi.org/10.5152/AnatolJCardiol.2015.6532
dc.identifier.doi10.5152/AnatolJCardiol.2015.6532
dc.identifier.endpage1029
dc.identifier.issn2149-2263
dc.identifier.issue12
dc.identifier.scopusqualityQ3
dc.identifier.startpage1020
dc.identifier.urihttps://hdl.handle.net/20.500.12511/505
dc.identifier.urihttps://doi.org/10.5152/AnatolJCardiol.2015.6532
dc.identifier.volume15
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAVES
dc.relation.ispartofThe Anatolian Journal of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectObesity
dc.subjectAnticoagulants
dc.subjectFactor xa Inhibitor
dc.subjectDabigatran
dc.subjectOral
dc.subjectFixed Dose
dc.titleA review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?
dc.typeOther

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
guler, ekrem-2015.pdf
Boyut:
121.01 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu